{"schema_version":"secwatch.filing_event.v1","accession":"0002019410-25-000020","form_type":"8-K","ticker":"CAI","cik":"0002019410","company_name":"Caris Life Sciences, Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.328203+00:00","generated_at":"2026-05-17T01:26:17.888878+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Caris Life Sciences adopts 3% ownership threshold for derivative proceedings","bullets":["Board approved amendment to bylaws on October 30, 2025 requiring 3% beneficial ownership to institute or maintain a derivative proceeding.","Threshold applies to any shareholder or group of shareholders acting together under the Texas Business Organizations Code.","Changes are effective immediately; full text of amended bylaws filed as Exhibit 3.1."],"urls":{"canonical":"https://secwatch.observer/filing/0002019410-25-000020","json":"https://secwatch.observer/filing/0002019410-25-000020.json","markdown":"https://secwatch.observer/filing/0002019410-25-000020.md","text":"https://secwatch.observer/filing/0002019410-25-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2019410/000201941025000020/0002019410-25-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2019410/000201941025000020/cai-20251030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:26:17.888878+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"010dc6c33a14db920e9fc8632406fa80843346bc","claim":"Caris Life Sciences, Inc.: Amended bylaws to require a shareholder (or group of shareholders acting together) to beneficially own at least 3% of outstanding shares to institute or maintain a derivative proceeding (effective 2025-10-30).","evidence_excerpt":"On October 30, 2025, the Board of Directors of Caris Life Sciences, Inc. (the “ Company ”) approved and adopted an amendment and restatement of the Company’s bylaws (the “ Bylaws ”) to provide that a shareholder (defined, in accordance with the Texas Business Organizations Code, to include a group of shareholders acting together) must beneficially own, at the time the derivative proceeding is instituted, a number of shares of common stock equal to at least three percent of the Company’s outstanding shares to institute or maintain a derivative proceeding.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941025000020/0002019410-25-000020-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2025-10-30"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}